• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NIH releases new priority list of drugs it wants tested in children

NIH releases new priority list of drugs it wants tested in children

August 28, 2014
CenterWatch Staff

The NIH has released a new "Priority List" of pediatric therapeutic areas and medical products it wants the medical community—including the pharmaceutical and biopharmaceutical industries—to focus on.

Historically, many companies seeking product approval in the U.S. avoided clinical studies involving children, wary of ethical problems, a lack of incentives and the potential consequences if testing uncovered new problems. As a result, many products lacked adequate dosing or safety information for children.

"We all know that children are not just small adults," said Lynne Yao, associate director of pediatric and maternal health staff in the FDA’s Center for Drug Evaluation and Research’s (CDER) Office of New Drugs (OND). Some drugs may be super-potent in children relative to adults, while others may not work at all. In either case, there are inherent safety risks.

To remedy this situation, Congress enacted two critical pieces of legislation: The Best Pharmaceutical for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), which combined provide new exclusivity-based incentives to conduct studies (BPCA), and allow the FDA to require companies to conduct pediatric studies as a condition of approval (PREA).

"Before BPCA and PREA became law, more than 80% of the drugs approved for adult use were being used in children, even though the safety and effectiveness had not been established in children," said Yao. "Today that number has been reduced to about 50%."

But the two laws differ in an important way: PREA requires companies to conduct post-market evaluations of their drugs in children, whereas the BPCA creates voluntary incentives for similar evaluations.

The BPCA, a 2002 law reauthorized in 2007 and 2012, allows the FDA to request a sponsor of a new drug study that product's effects in children. As NIH explained in a 2012 Federal Register notice, a lack of pediatric data "can increase a child's risk for unknown and/or adverse effects."

That's where the BPCA comes into play. In return for a sponsor conducting requested pediatric studies, a company becomes eligible for an additional six months of market exclusivity for a product's indication—the whole indication, and not just for its pediatric population. For blockbuster drugs that might generate billions in sales each year, the extra six months of exclusivity can be a powerful incentive.

But not all companies decide to take advantage of these incentives, often citing a lack of interest, ethical or legal concerns, difficulty enrolling patients or a lack of profit.

To address those cases, the BPCA also directs the NIH's National Institute of Child Health and Human Development (NICHD) to compile the Priority List of Needs of Pediatric Therapeutics (PLNPT) at least once every three years. Each year, the NICHD focuses on three therapeutic areas, it said.

The list, according to the NIH, represents the "drugs and therapeutic areas of highest priority for study in pediatric populations."

Once identified, the NIH and the FDA (or a sponsor) will develop Proposed Pediatric Study Requests (PPSRs) soliciting a manufacturer to conduct research on a drug in return for additional market exclusivity. If the manufacturer declines, the NIH will attempt to conduct its own research on the drug to better inform pediatric labeling.

The NIH has released its latest PLNPT for 2014, reflecting 17 categories of elevated need. The list includes 88 priority therapeutic areas, including several new ones such as sildenafil (Viagra), epogen, fluconazole (Diflucan) and epinephrine.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing